Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Advanced relapsed or refractory lymphoma presents significant treatment challenges.
• T-cell replete Haploidentical stem cell transplantation (Haplo-SCT) with Post-transplant cyclophosphamide (PT-Cy) is an emerging option.
• Existing transplant modalities have limitations in toxicity and efficacy.

Purpose of the Study:

• To evaluate the feasibility and outcomes of Haplo-SCT with PT-Cy for advanced lymphoma.
• To compare Haplo-SCT with PT-Cy to other stem cell transplant platforms.
• To identify areas for improvement in the Haplo-SCT platform.

Main Methods:

• Retrospective analysis of patient data undergoing Haplo-SCT with PT-Cy.
• Comparison of toxicity profiles, including acute and chronic graft-versus-host disease (GVHD).
• Assessment of disease relapse, non-relapse mortality, and survival outcomes.

Main Results:

• Haplo-SCT with PT-Cy demonstrates an improved toxicity profile compared to umbilical cord blood and mismatched unrelated donor transplants.
• Chronic GVHD incidence is reduced with Haplo-SCT with PT-Cy compared to unrelated donor and matched related donor transplants.
• Relapse-free/GVHD-free survival is promising, though non-relapse mortality, particularly from infections, remains an area for concern.

Conclusions:

• Haplo-SCT with PT-Cy is a feasible and promising therapeutic option for advanced lymphoma.
• This platform offers advantages in GVHD reduction and survival outcomes.
• Future research should focus on mitigating infections and leveraging Haplo-SCT for novel immunotherapies.